Decision/Other
Adopted
Approval of clinical trial for SIM0725 in China
China's NMPA approved a clinical trial of Simcere's self-developed long-acting anti-CD122 monoclonal antibody SIM0725 for autoimmune diseases, allowing the company to begin testing it in patients in China.
Actors and targets
Targets SIM0725item
Source
已獲國家藥品監督管理局批准在中國開展臨牀試驗
Extracted detail
Related decisions
Same kind only, ranked by embedding similarity to this record.